Emerging Strategies in the Management of Chronic Fibrosing ILD Patients Who Have Contracted COVID-19

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by MedNet, LLC and Amedco, LLC.

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

• Physicians, Physician Assistants, Nurse Practitioners — maximum of 1.5 AMA PRA Category 1 Credit(s)™
• Nurses — 1.5 Nursing Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of pulmonologists, radiologists, pathologists, primary care physicians, physician assistants, registered nurses, nurse practitioners, pharmacists, fellows, residents, and other allied HCPs involved in the management of patients with CF-ILD.

Program Overview

This activity will cover topics on the diagnosis, treatment, and management of patients with chronic fibrosing ILD and CF-ILD patients who have contracted COVID-19.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Evaluate the pathophysiology, prevalence, morbidity, mortality, signs, and symptoms of ILDs with a progressive fibrosing phenotype who have contracted COVID-19
• Assess the potential of high-resolution computed tomography (HRCT) and quantitative computed tomography (CT) analysis as the primary tool for the diagnosis of progressive fibrosing phenotype
• Cite emerging strategies to increase clinician's awareness of induced severe lung injury and acute respiratory distress syndrome (ARDS) in patients with progressive pulmonary fibrosis recovering from COVID 19

Faculty

Accreditation Statement

Physicians, Nurse Practitioners, Physician Assistants, and Nurses

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians, Nurse Practitioners, Physician Assistants, and Nurses Credit Designation

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™ for physicians, nurse practitioners, and physician assistants and 1.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved (C7 SCS 6.1-¬‐6.2, 6.5). All individuals in a position to control the content of CE are listed below.

Justin M. Oldham, MD, MS

• Grants:
  • National Institutes of Health (NHLBI)
    • K23 (Oldham) – Genomic determinants of IPF outcomes
    • R01 (Chen) – MARCKS signaling in IPF
    • R01 (Fernandez-Perez) - Transcriptomic signature of hypersensitivity pneumonitis
    • UG3/UH3 (FJ Martinez/Noth) - PRECISIONS IPF clinical trial and genomic sequencing
  • CA Tobacco Related Disease Research Program
    • MARCKS signaling in IPF (Chen)
  • American College of Chest Physicians
    • Pulmonary Fibrosis Award (Oldham) - Plasma Biomarkers of ILD outcomes
• Consultant: Genentech and Boehringer Ingelheim

Brian D. Southern, MD

• Has no relevant financial relationships to disclose.

Planners and Managers Dislcosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

• Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships.
• Brian Waggoner (MedNet, LLC) has no relevant financial relationships to disclose.
• Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

 

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

1. Read the CME/CE information and faculty disclosures..
2. Participate in the online activity.
3. Submit the evaluation form to the Med Learning Group.
4. Certificates will be emailed to participants.

 

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Amedco and MedNet require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME/CE questions, please contact: Amedco at certificate@amedcoemail.com

For questions regarding content, please contact: MedNet at brianw@mednetus.com